FDA of Ghana Blacklisted Bliss GVS Pharma Limited

Oct 7, 2013 13:40 IST

The Food and Drugs Authority (FDA) of Ghana on 4 October 2013 banned the importation and distribution of all medicinal products manufactured by an Indian company Bliss GVS Pharma Limited, India.

While announcing the ban on Bliss GVS Pharma Limited in Ghana, the Food and Drugs Authority (FDA) told that the company is not following the registration requirements as enshrined in the Public Health Act of 2012, Act 851, a process which assures the quality, safety and efficacy of all medicinal products.

The official of FDA also told that the company manufactured a fake anti-malarial medicine (GSUNATE PLUS SUPPOSITORIES). The efficacy and safety of this anti-malarial medicine has not been ascertained since there has not been any clinical trial study to justify the use of this medicinal product for the treatment of Malaria.

He also explained that the company also manufactured and distributed onto the Ghanaian market many other medicinal products, which have not been evaluated and duly registered as required by law.

He also explained that Malaria is the number one cause of Out Patients Department (OPD) attendance and the highest cause of child mortality (death) in Ghana. The use of fake anti-malarial medicine can result in treatment failures, complications and preventable deaths in children.

Is this article important for exams ? Yes42 People Agreed
Read more Current Affairs on: Food and Drugs Authority , Ghana

DISCLAIMER: JPL and its affiliates shall have no liability for any views, thoughts and comments expressed on this article.

Latest Videos

Register to get FREE updates

    All Fields Mandatory
  • (Ex:9123456789)
  • Please Select Your Interest
  • Please specify

  • ajax-loader
  • A verifcation code has been sent to
    your mobile number

    Please enter the verification code below

This website uses cookie or similar technologies, to enhance your browsing experience and provide personalised recommendations. By continuing to use our website, you agree to our Privacy Policy and Cookie Policy. OK